Labiotech.eu

News and Trends 6 Sep 2022

Innovent starts trial of mazdutide in Chinese adults with obesity

Innovent Biologics, Inc. says the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity. This randomized, double-blinded, placebo-controlled study was designed to evaluate the efficacy and safety of mazdutide […]

September 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Pleco Therapeutics raises €17.3M to develop AML product

Pleco Therapeutics BV, a specialty biopharmaceutical company in the Netherlands developing novel treatments designed to detoxify the cancer micro-environment has raised total funds of €17.3 million ($17.2 million) in series A financing. The funds will be used to complete development of, and to commercialize, the company’s novel lead Plecoid product, PTX-061, to improve the effectiveness […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children

A maintenance therapy from Sanofi and Regeneron, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years in children. Results from the longest global phase 3 open-label extension trial in the age group six to 11 years old with […]

September 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

Astellas ‘encouraged’ by menopause symptom treatment results in China

Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […]

September 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […]

September 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

A drug to treat soft tissue sarcoma has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Clinical stage oncology drug company Avacta Group plc has produced a form of the generic chemotherapy, doxorubicin AVA6000. About Avacta’s drug The drug has been modified using the company’s pre|CISION technology and Affirmer […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Sep 2022

Abivax pulls in €49.2M but needs more to complete ulcerative colitis program

French biotech company Abivax has completed an oversubscribed €49.2 million ($49 million) financing round. This included U.S. and European biotech specialist investors, led by TCGX, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus, and Truffle Capital through the completion of two transactions. The first was a reserved capital increase of […]

September 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Neukio Biotherapeutics completes financing round for development of cell therapy products

Neukio Biotherapeutics, a Chinese company committed to developing novel cell therapy products, has closed $50 million in a series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital as new investors. Existing shareholders Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital have continued […]

September 2, 2022 - 2 minutesmins - By Jim Cornall

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 2 Sep 2022

Ibex reports positive outcomes for AI-supported diagnosis of breast cancer

Ibex Medical Analytics have just announced positive outcomes for its Galen Breast solution in diagnosing multiple cancer types and further expanding its portfolio for breast cancer diagnosis. The CE-marked artificial-intelligence is generally available as the company partners with laboratories, hospitals and health systems across Europe. Ibex Medical Analytics says Galen Breast supports improved quality and […]

September 2, 2022 - 4 minutesmins - By Liza Laws

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […]

September 2, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Innovent starts trial of mazdutide in Chinese adults with obesity

Pleco Therapeutics raises €17.3M to develop AML product

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children

Astellas ‘encouraged’ by menopause symptom treatment results in China

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

Abivax pulls in €49.2M but needs more to complete ulcerative colitis program

Neukio Biotherapeutics completes financing round for development of cell therapy products

Ibex reports positive outcomes for AI-supported diagnosis of breast cancer

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!